Source link : https://newshealth.biz/health-news/fda-advisory-daratumumab-wins-glofitamab-loses/
Daratumumab and hyaluronidase (Darzalex Faspro, Johnson & Johnson) came a step closer to being approved for high-risk smoldering multiple myeloma (SMM) on Tuesday after the Oncologic Drugs Advisory Committee (ODAC) of the US Food and Drug Administration (FDA) voted that the benefits outweigh the risks. However, the prospects of glofitamab (Columvi, Roche) for relapsed/refractory diffuse […]
The post FDA Advisory: Daratumumab Wins, Glofitamab Loses first appeared on News Health.
—-
Author : News Health
Publish date : 2025-05-22 13:28:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8